Abstract: A multifunctional unified structure thermal plate and system for supporting a plurality of battery cells included as part of a high voltage battery pack. The plate may include a bottom plate and a plurality of crossbeams configured for supporting the battery cells, with the bottom plate and the crossbeams together being from as a monolithic, one-piece structure.

Abstract: The present application provides a composition of oral soluble film and application thereof. The composition includes a film-forming agent, a plasticizing agent, and a target releasing substance. The film-forming agent includes pectin and polysaccharide backbones. The flexibility and mechanical strength of the oral soluble film may meet the production requirements during cutting and packaging processes, the adhesion force, the dissolving time limit, and the dissolving rate of the active components may also meet usage needs.

Abstract: A method for designing an accelerated battery aging testing protocol from battery electric vehicle usage data is provided. An initial search space database is created based on a collection of vehicle usage data. The usage data includes current demand over a first timeframe. Data compression is performed including classifying the database into specific segments representing use events. A synthetic profile is generated including a sequence of elements having a battery current and a battery state of charge (SOC) for selected segments of the specific segments. An optimization for accelerated aging of the battery is defined. A genetic algorithm (GA) is executed that generates the accelerated battery aging testing protocol requiring a second timeframe, shorter than the first timeframe, based on the optimization.

Abstract: Provided in the present disclosure is a compound of formula (I), or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, which is an extrahepatic targeted cationic lipid compound with high efficiency and low toxicity. Further provided are a composition containing the aforementioned compound, and the use thereof in the delivery of a therapeutic or prophylactic agent.

Abstract: The present disclosure describes a multi-function, integrated Super Beam assembly structure with integrated structural, cooling, and transverse elastic compliance functions; and Thermal Management Propagation (TMP) protection. The Super Beam assembly includes a pair of parallel face plates, coolant channel cover plates, and coolant channels that are defined by the face plate and the one or more coolant channel cover plates. The structural design of the cooling channels, and the corresponding air gaps formed in-between them, allows a transverse elastic compliance of the Super Beam assembly to be tuned to different amounts of elasticity. Top, bottom and/or end structural channels may be included. A pair of TMP suppression channels may be attached to the Super Beam assembly structure with an adhesive “thermal fuse” that preferentially melts and causes the pair of TMP suppression channels to detach from the Super Beam assembly during overheating in a TMP event.

Abstract: A battery pack includes a first header having a first conduit and a second header having a second conduit. The battery pack also includes an energy storage system having energy storage cells arranged between the first header and the second header. A coolant plate assembly is arranged between the first header and the second header and abuts the plurality of energy storage cells. The coolant plate assembly includes a coolant channel having a first end fluidically connected to the first conduit, a second end fluidically connected to the second conduit, and an intermediate portion defining a flow path. The coolant plate assembly also includes a first planar section having a first surface facing the energy storage cells and a second surface having protrusions extending into the coolant channel.

Abstract: A modular multi-cell rechargeable energy storage system (RESS) includes a RESS enclosure surrounded by an external environment and having an enclosure tray and an enclosure cover. The RESS also includes a plurality of battery cell blocks arranged in the RESS enclosure. Each battery cell block includes a cell case including a cell vent and at least one electrically insulated structural connector configured to link the cell case with an adjacent battery cell block. Each battery cell block also includes a thermal mitigation barrier (TMB) segment fixed to the cell case and configured to contact the adjacent battery cell block. Each battery cell block additionally includes a thermal insulator configured to line the cell vent. Furthermore, each battery cell block includes a bus bar segment configured to interconnect with a bus bar segment of the adjacent battery cell block.

Abstract: A compound of Formula I or pharmaceutically acceptable compositions thereof, is useful to as a TLR7/8 antagonist.

Abstract: The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

Abstract: A method of administering to a patient in need thereof or contacting with a biological sample, a compound related to Formula I-e or pharmaceutically acceptable compositions thereof, is useful to inhibit activity of TLR7/8 or a mutant thereof and/or to treat a TLR7/8-mediated disorder.

Abstract: Provided is a method for determining a quality level of an iron and steel product. The method includes: obtaining a plurality of first parameters related to a quality of an iron and steel product; fusing the plurality of first parameters to obtain a comprehensive quality evaluation parameter; and determining a quality level of the iron and steel product based on the comprehensive quality evaluation parameter.

Abstract: Compounds of Formula (I) and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.

Abstract: The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

Abstract: The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.